Klotho Neurosciences Concludes Its Agreement with Turn Biotechnologies

On October 7, 2025, Klotho Neurosciences, Inc. (Nasdaq: KLTO) made headlines by announcing the expiration of its Letter of Intent with Turn Biotechnologies. The decision was made after a thorough review by the company's Board of Directors, which concluded that the proposed collaboration didn't align with Klotho's long-term strategic objectives. Instead, the organization plans to concentrate its efforts on advancing its Klotho anti-aging protein research pipeline, aiming to develop treatments that could significantly benefit both patients and shareholders.

A Growing Focus on Longevity Medicine

The longevity medicine market is one of the fastest-growing sectors in healthcare, rapidly expanding as the global population ages. By 2050, it's projected that the world will have approximately 2.1 billion people aged 60 years or older. This demographic change places immense pressure on healthcare systems, with related costs expected to surpass $47 trillion by 2030, consuming over 10% of the global GDP. Klotho recognizes the importance of this shift and aims to leverage its research efforts to capitalize on emerging opportunities in this field.

Klotho's research focuses on the human Klotho protein, which is considered a crucial factor in promoting longevity. By investing in this area, Klotho intends to develop innovative solutions to combat age-related diseases and improve human health outcomes.

Company Overview

Klotho Neurosciences, Inc. is highly specialized in biogenetics, emphasizing the creation of pioneering cell and gene therapies that utilize a patented form of the human Klotho gene. Through these innovative therapies, Klotho aims to transform how we approach the treatment of neurodegenerative and age-related disorders, including Alzheimer’s disease, Parkinson’s disease, and Amyotrophic Lateral Sclerosis (ALS).

With a robust portfolio that includes proprietary programs focused on DNA and RNA therapeutics, Klotho combines advanced genomics with clinical applications to address critical healthcare needs. This hallmark approach is designed to improve patient care and potentially offer solutions where conventional treatments fall short.

The leadership team at Klotho is composed of experienced professionals from the biopharmaceutical industry, all committed to the company's mission of advancing healthcare through scientific innovation and discovery.

Looking Ahead

As Klotho moves forward from the expiration of its agreement with Turn Biotechnologies, it is redirecting its resources and energy toward its core research initiatives. The decision to prioritize the anti-aging protein studies aligns seamlessly with the company's overarching strategy to lead in developing significant therapies through cutting-edge biogenetics.

While Klotho does not provide specific timelines for upcoming projects, the potential market demand for effective longevity treatments reinforces the company's mission and purpose. In a rapidly evolving healthcare landscape, Klotho is poised to make valuable contributions to the fight against age-related diseases, all aimed at enhancing the quality of life for the aging population.

In summary, Klotho Neurosciences’ decision to let the Letter of Intent with Turn Biotechnologies lapse reflects a calculated strategy focused on harnessing the power of the Klotho protein for innovative advancements in longevity medicine. The future looks promising for Klotho as they set their sights on impactful research that stands to shape the future of healthcare for the elderly.